PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIbutilide
Ibutilide
Corvert, Ibutilide (ibutilide) is a small molecule pharmaceutical. Ibutilide was first approved as Corvert on 1995-12-28. It is used to treat atrial fibrillation, atrial flutter, and cardiac arrhythmias in the USA. The pharmaceutical is active against voltage-gated inwardly rectifying potassium channel KCNH2; potassium voltage-gated channel subfamily H member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Corvert, Ibutilide (discontinued: Ibutilide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ibutilide fumarate
Tradename
Company
Number
Date
Products
CORVERTPfizerN-020491 RX1995-12-28
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
corvertNew Drug Application2024-01-25
ibutilide fumarateANDA2024-03-13
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01B: Antiarrhythmics, class i and iii
C01BD: Antiarrhythmics, class iii
C01BD05: Ibutilide
HCPCS
Code
Description
J1742
Injection, ibutilide fumarate, 1 mg
Clinical
Clinical Trials
9 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0145
Long qt syndromeD008133HP_0001657I45.81134
Torsades de pointesD016171EFO_0005307I47.21112
Drug-induced abnormalitiesD00001422
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Jervell-lange nielsen syndromeD029593Orphanet_90647I45.811
Sudden deathD00364511
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIbutilide
INNibutilide
Description
Ibutilide is an organic amino compound and a member of benzenes.
Classification
Small molecule
Drug classclass III antiarrhythmic agents
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1
Identifiers
PDB
CAS-ID122647-31-8
RxCUI
ChEMBL IDCHEMBL533
ChEBI ID5856
PubChem CID60753
DrugBankDB00308
UNII ID2436VX1U9B (ChemIDplus, GSRS)
Target
Agency Approved
KCNH2
KCNH2
Organism
Homo sapiens
Gene name
KCNH2
Gene synonyms
ERG, ERG1, HERG
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 2
Protein synonyms
Eag homolog, Eag-related protein 1, ERG-1, Ether-a-go-go-related gene potassium channel 1, ether-a-go-go-related potassium channel protein, Ether-a-go-go-related protein 1, H-ERG, hERG-1, hERG1, human ether-a-go-go-related, long QT syndrome type 2, potassium channel, voltage gated eag related subfamily H, member 2, potassium voltage-gated channel, subfamily H (eag-related), member 2, Voltage-gated potassium channel subunit Kv11.1
Uniprot ID
Mouse ortholog
Kcnh2 (16511)
potassium voltage-gated channel subfamily H member 2 (O35989)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,012 documents
View more details
Safety
Black-box Warning
Black-box warning for: Corvert
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
45 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use